TheraVet Reports Full Year 2021 Financial Results and Confirms Its Ambitious Development and Commerc

Positive safety and efficacy results for BIOCERA-VET® (arthrodesis and canine osteosarcoma) and VISCO-VET® (canine osteoarthritis)Initiation of the pivotal European multicentric clinical study evaluating VISCO-VET® in canine osteoarthritisCommercialization of BIOCERA-VET® Bone Surgery and BIOCERA-VET® Osteosarcoma i...

Related Keywords

Germany ,United States ,Paris ,France General ,France ,Netherlands ,United Kingdom ,Texas ,Wallonia ,Waals Gewest ,Belgium ,Portugal ,Ireland ,Poland ,Brussels ,Bruxelles Capitale ,Gosselies ,Switzerland ,America ,Belgian ,American ,Martin Olivier Bricaud ,Enrico Bastianelli ,Arthur Rouill ,Industrie Biomediche Insubri ,Ambre Delval ,Newcap Belgique ,Financial Communications ,Bone Surgery ,Regulatory News ,Chief Executive Officer ,Initial Public Offering ,Initial Public ,Veterinary Orthopedic Conference ,Regulatory Agencies ,General Assembly ,Olivier Bricaud ,